Quantcast

Latest Cetuximab Stories

2010-10-26 11:13:45

(Ivanhoe Newswire) -- Taking back the years the fears and anxieties of having cancer may have brought are possible. Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Systemic chemotherapy is treatment with anticancer drugs that travel through the bloodstream, reaching and affecting cells all over the body. While radiation therapy utilizes x-rays at very high doses to...

2010-10-25 23:48:19

Studies have shown higher survival rates for people with head and neck cancers that test positive for HPV when they are treated with systemic chemotherapy and radiation therapy. Now a new study suggests outcomes are also better when radiation therapy is combined with cetuximab, a targeted therapy. The data will be presented at the annual meeting of the American Society for Radiation Oncology, October 31st through November 4th in San Diego. The study, conducted at Georgetown Lombardi...

2010-10-12 18:07:56

New data reported at the 35th ESMO Congress A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have...

2010-10-12 16:42:21

Adding the targeted drug cetuximab to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival or overall survival, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Professor Kjell Magne Tveit from Oslo University Hospital, Norway, reported the unexpected results from the NORDIC VII study, which included 566 patients from Sweden, Denmark,...

2010-10-04 16:05:00

THOUSAND OAKS, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology. "Both studies demonstrated that Vectibix administered with chemotherapy...

2010-09-22 11:31:00

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from...

2010-09-08 01:00:00

SAN FRANCISCO and ILLKIRCH, France, Sept. 8 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the...

2010-08-19 08:36:00

ROME, August 19, 2010 /PRNewswire/ -- Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of...

2010-08-11 08:20:00

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced top-line results from a randomized Phase 3 trial evaluating Vectibix® (panitumumab) as a first-line treatment in patients with recurrent and/or metastatic squamous cell head and neck cancer. The data showed the addition of Vectibix to platinum-based chemotherapy did not result in a statistically significant improvement in overall survival, the primary endpoint, compared to...

2010-07-27 01:15:05

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs. Specifically, the team found that human cancer cells with mutations in the PIK3CA gene responded to everolimus in vitro except when a KRAS gene mutation was also present....


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related